BOSTON– Ibex Medical Analytics has entered a strategic collaboration with HNL Lab Medicine to deploy artificial intelligence technology aimed at enhancing prostate cancer diagnostics and workflow efficiency.
Under the agreement, HNL Lab Medicine will integrate Ibex’s AI-powered solution, Ibex Prostate, into its existing digital pathology infrastructure to assist in analyzing biopsies and transurethral resection of the prostate procedures. The platform is designed to support pathologists in detecting and grading cancer, while helping ensure that suspicious findings are not overlooked.
The partnership builds on HNL Lab Medicine’s digital pathology foundation, which has included the use of Proscia’s Concentriq platform and Leica Biosystems’ imaging systems since 2023. With the addition of Ibex’s technology, the organization is transitioning from a digital workflow to an AI-enabled diagnostic environment.
Company officials said the deployment represents a key step in advancing precision diagnostics, with the AI system embedded directly into existing workflows to improve efficiency and diagnostic confidence.
“We are thrilled to partner with HNL Lab Medicine, an organization that exemplifies the future of pathology,” said Yair Heller, CEO of Ibex Medical Analytics. ” HNL Lab Medicine’s ability to operate as a high-volume independent lab while maintaining the clinical rigor of a health system makes them an ideal partner for our technology. By integrating Ibex’s AI into their established digital workflow, HNL Lab Medicine is ensuring that their pathologists have advanced tools available to provide timely, high-confidence results for every patient.”
“HNL Lab Medicine is unique because we partner closely with health systems, embedding members of our team within their organizations while operating at the scale of a full-service clinical laboratory,” said Dr. Jordan Olson, Chief Medical Officer at HNL Lab Medicine. “That collaboration gives us insight into where innovation can make the biggest difference, which is why integrating Ibex’s AI is such a powerful step forward for our pathologists.”
The companies said the initial deployment, conducted within HNL Lab Medicine’s lab-developed test workflow for prostate cancer, is expected to serve as a foundation for expanding the use of AI-powered diagnostics across additional clinical applications.
